Interview with Dominique Amory, President, Lilly France
There is a lot of activity in the pharmaceutical industry and France is no exception especially having passed Germany as the major market of Europe over the past year which…
Address: 24 Boulevard Vital Bouhot
CS 50004
92521 Neuilly-sur-Seine Cedex
Tel: 01 55 49 34 34
Web: http://www.lilly.com/Pages/home.aspx
The Pharmaceutical company Lilly has been in France since 1962. This is the 4th subsidiary of Lilly after the United States, Japan and Germany.
Lilly France is the 16th French pharmaceutical company and has a turnover of 2.3 billion euros in 2008, including 1.6 billion under its manufacturing (factory Fegersheim).
Advancing medicine, contributing to major therapeutic advances, allowing everyone to live better and longer: this is the mission of the pharmaceutical company Lilly.
Eli Lilly and Company is a specialty pharmaceutical company entirely focused on innovation and committed to developing a portfolio of drugs to both the best and the first in their class, to allow patients to be healthier and live a longer and more active.
To do this, we use the results of recent medical studies in our laboratories pharmaceutical world. We are collaborating with eminent scientific organizations, and we appeal to the most advanced technological tools, while ensuring the high quality service to our customers.
Through internal programs and external initiatives, we intend to meet the most urgent medical needs. Lilly employs more than 40 450 people worldwide and markets its medicines in 143 countries. The company has major research and development centers in 9 countries and conducts clinical trials in over 50 countries.
Lilly’s drugs treat depression, schizophrenia, cancer, diabetes, osteoporosis and other disorders.
There is a lot of activity in the pharmaceutical industry and France is no exception especially having passed Germany as the major market of Europe over the past year which…
The Director-General of the Gustave Roussy Institute, a top cancer institute in Europe, talks about the revamping of their clinical research infrastructure to adapt to the rising new field of…
Anne-Marie Noir discusses footcare, Laboratoires Asepta’s corporate values, the strategic development behind their innovative brand, and the company’s positioning in Monaco. She also discusses her family’s legacy in the business…
Carlos Jaime, Head of Samsung’s Health & Medical Equipment Division, France, explains why the future of healthcare is in mobile technology and communications, and how Samsung’s expertise in “digital transformations”…
Yann Quentric has assumed new responsibilities as president of Iris Pharma; leading the first CRO to specialize exclusively in ophthalmology. From the company’s humble beginnings in southern France to its current…
Marc de Garidel reveals how 2015 has been Ipsen’s best year since becoming publicly traded, marked by their take-off in the US, and how in 2016 the US will overtake…
Laurent Levy, CEO at Nanobiotix, is leading the way in nanomedicine with new market-disruptive developments, establishing a growing presence in European and global research labs and pushing back the frontiers in healthcare, for the industry…
Eric Le Roy, CEO of the SNITEM (Syndicat National de l’Industrie des Technologies Médicales, The National Association of Medical Technologies Industry), reveals how the French medical devices market is valued at…
Boasting a more than 14 percent growth rate in 2015, AbbVie has cemented its status as a top 20 pharmaceutical company in France. Sharing the unique relationship the company has…
Jean-Luc Bélingard, chairman of bioMérieux, reveals how the medical community in France has a unique profile, combining both clinical and technological experience, leading to what he describes as the best…
Stéphane Bouchard reveals why BD’s pharmaceutical systems centre of excellence is based in France; BD’s increased strength in medical devices following the acquisition of CareFusion in 2015; and why cooperation and transparency between medical device…
Frédéric Duchesne, President & CEO of Pierre Fabre’s pharmaceuticals division, talks about the the four main pillars at the heart of Trajectoire 2018, a strategic plan approved in December 2014:…
While functional outsourcing may be common for companies seeking services from CROs, Medpace believes that their robust, physician-led, full-service business model is the most efficient way to conduct clinical research.…
See our Cookie Privacy Policy Here
